Designing and In silico Studies of Novel Hybrid of 1,3,4-oxadiazolechalcone Derivatives as EGFR Inhibitors

Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..

BACKGROUND: The tyrosine kinase epidermal growth factor receptor (TK-EGFR) has recently been identified as a useful target for anticancer treatments. The major concern for current EGFR inhibitors is resistance due to mutation, which can be overcome by combining more than one pharmacophore into a single molecule.

AIM AND OBJECTIVE: In the present study, various hybrids of 1,3,4-oxadiazole-chalcone derivatives were gauged for their EGFR inhibitory potential.

METHOD: The design of 1,3,4-oxadiazole-chalcone hybrid derivatives was carried out and in silico studies, viz., molecular docking, ADME, toxicity, and molecular simulation, were performed as EGFR inhibitors. Twenty-six 1,3,4-oxadiazole-chalcone hybrid derivatives were designed using the combilib tool of the V life software. AutoDock Vina software was used to perform in silico docking studies, while SwissADME and pkCSM tools were used to analyse molecules for ADME and toxicity. Desmond software was used to run the molecular simulation.

RESULT: Around 50% of molecules have shown better binding affinity as compared to standard and cocrystallized ligands.

CONCLUSION: Molecule 11 was found to be a lead molecule that has the highest binding affinity, good pharmacokinetics, good toxicity estimates and better protein-ligand stability.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:20

Enthalten in:

Current drug discovery technologies - 20(2023), 6 vom: 08., Seite 47-59

Sprache:

Englisch

Beteiligte Personen:

Patil, Shital M [VerfasserIn]
Shashikant, Bhandari [VerfasserIn]

Links:

Volltext

Themen:

Anti-cancer
Derivatives
Docking
EGFR inhibitors
Journal Article
Oxadiazole-chalcone
Simulation

Anmerkungen:

Date Revised 24.10.2023

published: Print

Citation Status Publisher

doi:

10.2174/1570163820666230608120944

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM357935667